Indoco Remedies Ltd
NSE: INDOCO BSE: 532612
₹192.20
(1.80%)
Tue, 24 Mar 2026, 02:49 am
Market Cap17.66B
PE Ratio0
Dividend0.10
Health Technology
Pharmaceuticals: Major
24.5KIndoco Remedies Analysis
dividend
- Indoco Remedies is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Indoco Remedies's dividends as it is not paying a notable one for India.
- Indoco Remedies is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Indoco Remedies's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Indoco Remedies's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Indoco Remedies's earnings are expected to grow significantly at over 20% yearly.
- Indoco Remedies's earnings growth is expected to exceed the India market average.
- Indoco Remedies's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Indoco Remedies's earnings are expected to exceed the low risk growth rate next year.
- Indoco Remedies's net income is expected to increase by more than 50% in 2 years time.
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- An improvement in Indoco Remedies's performance (ROE) is expected over the next 3 years.
- Indoco Remedies's revenue growth is expected to exceed the India market average.
- Cash flow for Indoco Remedies is expected to decrease over the next 2 years.
- Indoco Remedies is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- Indoco Remedies's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Indoco Remedies's revenue is expected to grow by 19.1% yearly, however this is not considered high growth (20% yearly).
health
- Indoco Remedies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Indoco Remedies is profitable, therefore cash runway is not a concern.
- Indoco Remedies is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (61.7%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 2.8x debt.
- Indoco Remedies's cash and other short term assets cover its long term commitments.
- Indoco Remedies's level of debt (32.1%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (18.9% vs 32.1% today).
- Interest payments on debt are not well covered by earnings (EBIT is 2.5x annual interest expense, ideally 3x coverage).
- High level of physical assets or inventory.
management
- The average tenure for the Indoco Remedies board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Sundeep's remuneration is lower than average for companies of similar size in India.
- Sundeep's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Indoco Remedies management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- Indoco Remedies is covered by less than 3 analysts.
- Indoco Remedies has significant price volatility in the past 3 months.
past
- Indoco Remedies's 1-year earnings growth exceeds its 5-year average (279.8% vs -37.7%)
- Indoco Remedies's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (279.8% vs 22.7%).
- Indoco Remedies's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Indoco Remedies used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Indoco Remedies's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Indoco Remedies has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Indoco Remedies is good value based on expected growth next year.
- INDOCO outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- INDOCO outperformed the Market in India which returned -14.5% over the past year.
- Indoco Remedies's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Indoco Remedies's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Indoco Remedies is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Indoco Remedies is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Indoco Remedies is overvalued based on earnings compared to the India market.
- NSEI:INDOCO is down -3.9% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:INDOCO is down -3.9% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800